A Clinical Study of SCH 54031 [peginterferon alfa 2b] as Monotherapy in IFN[Interferon]-Treated Patients With Chronic Hepatitis C.

Trial Profile

A Clinical Study of SCH 54031 [peginterferon alfa 2b] as Monotherapy in IFN[Interferon]-Treated Patients With Chronic Hepatitis C.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2013

At a glance

  • Drugs Glycyrrhizin; Peginterferon alfa-2b
  • Indications Hepatic fibrosis; Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Mar 2012 Planned end date changed from 1 Jul 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top